B. Ference
Genetics · 2012–2022
A researcher in the Science corpus: 12 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Genetics — 86 citations into it
- Statistics and Probability — 14 citations into it
Whom B. Ference trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- J. Bowden
- George Davey Smith
- Deborah Lawlor
- B. J. Gersh
- Jonathan C. Cohen
- G. Moneta
- Improve-It Investigators
- W. J. Howard
Papers from B. Ference's perspective
Ordered by how strongly the researchers B. Ference trusts endorse each paper. Same corpus, a different order for every researcher.
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. (Journal of the American Medical Association (JAMA))
- Mendelian randomization: genetic anchors for causal inference in epidemiological studies (Human Molecular Genetics)
- Rosuvastatin in older patients with systolic heart failure. (Current Atherosclerosis Reports)
- C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. (New England Journal of Medicine)
- An expanded view of complex traits: from polygenic to omnigenic (Cell)
- Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA (Nature Communications)
- 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? (International Journal of Epidemiology)
- A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization (Statistics in Medicine)
- Interpretation of the evidence for the efficacy and safety of statin therapy. (The Lancet)
- Large-scale association analyses identifies 13 new susceptibility loci for coronary artery disease (Nature Genetics)
Their papers
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. (2021) — 5,029 citations
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement (2022) — 1,097 citations
- SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. (2021) — 1,383 citations
- Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) — 742 citations
- Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis (2020) — 681 citations
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) — 1,302 citations
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019) — 4,665 citations
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. (2019) — 3,945 citations
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) — 3,303 citations
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. (2016) — 670 citations
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. (2016) — 1,332 citations
- Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. (2012) — 843 citations